Multiple other studies have similarly concluded that maternal inflammatory biomarkers (IL-6 (AUC 0.62)/IL-10 (AUC 0.595)/GCSF (0.602)) lack accuracy in predicting neonatal adverse outcome in the setting of PPROM and therefore should not be used to guide clinical practice [69]. This evidence concerns the gene IL10 and preterm premature rupture of the membranes.